FibroBiologics prices 4.48M shares at 33.5c in registered direct offering

FibroBiologics (FBLG) entered into definitive agreements for the issuance and sale of an aggregate of 4,477,614 shares of its common stock at an offering price of $0.335 per share of common stock in a registered direct offering priced at-the-market under Nasdaq rules. Additionally, in a concurrent private placement, the Company will issue and sell unregistered warrants to purchase up to an aggregate of 4,477,614 shares of common stock at an exercise price of $0.335 per share. The unregistered warrants will be exercisable beginning on the effective date of, and subject to, approval by the Company’s stockholders of the issuance of the shares of common stock upon exercise of the unregistered warrant and will expire five years following the date of Stockholder Approval. The closing of the offering is expected to occur on or about November 25, 2025, subject to the satisfaction of customary closing conditions. H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.